These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24762072)

  • 1. Benefits of a continuous therapy for cancer patients with a novel adoptive cell therapy by cascade priming (CAPRI).
    Wank R; Song X; Gu S; Laumbacher B
    Immunotherapy; 2014; 6(3):269-82. PubMed ID: 24762072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated monocytes prime naïve T cells against autologous cancer: vigorous cancer destruction in vitro and in vivo.
    Laumbacher B; Gu S; Wank R
    Scand J Immunol; 2012 Mar; 75(3):314-28. PubMed ID: 21995310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
    Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell-associated cellular immunotherapy for lung cancer.
    Li K; Zhang Q; Zhang Y; Yang J; Zheng J
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1249-58. PubMed ID: 25381064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
    Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
    Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.
    Kass R; Bellone S; Palmieri M; Canè S; Bignotti E; Henry-Tillman R; Hutchins L; Cannon MJ; Klimberg S; Santin AD
    Breast Cancer Res Treat; 2003 Aug; 80(3):275-85. PubMed ID: 14503800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
    Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
    Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Generation and activation of tumor-infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK-TIL therapy) in patients with advanced breast and ovarian carcinoma].
    Mallmann P; Krebs D
    Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():161-5. PubMed ID: 8672919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive cellular immunotherapy of cancer.
    Winter H; Fox BA
    Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690
    [No Abstract]   [Full Text] [Related]  

  • 11. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
    Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
    Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
    Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
    Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive T-cell immunotherapy of cancer.
    Li Q; Chang AE
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):105-17. PubMed ID: 10515683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor enhancement by adoptive transfer of tumor antigen primed, inactivated MHC-haploidentical lymphocytes.
    Shi G; Zhou C; Wang D; Ma W; Liu B; Zhang S
    Cancer Lett; 2014 Feb; 343(1):42-50. PubMed ID: 24045039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CD4+ effector T cells mediate indirect interleukin-12- and interferon-gamma-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice.
    Egilmez NK; Hess SD; Chen FA; Takita H; Conway TF; Bankert RB
    Cancer Res; 2002 May; 62(9):2611-7. PubMed ID: 11980657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation.
    Toso JF; Oei C; Oshidari F; Tartaglia J; Paoletti E; Lyerly HK; Talib S; Weinhold KJ
    Cancer Res; 1996 Jan; 56(1):16-20. PubMed ID: 8548758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular immunotherapy of cancer.
    Yang JC
    Curr Opin Gen Surg; 1994; ():238-44. PubMed ID: 7583979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.
    Melief CJ; Kast WM
    Semin Cancer Biol; 1991 Oct; 2(5):347-54. PubMed ID: 1773050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility study of adoptive immunotherapy for metastatic lung tumors using peptide-pulsed dendritic cell-activated killer (PDAK) cells.
    Yamaguchi Y; Ohta K; Kawabuchi Y; Ohshita A; Okita R; Okawaki M; Hironaka K; Matsuura K; Toge T
    Anticancer Res; 2005; 25(3c):2407-15. PubMed ID: 16080467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From the study of tumor cell immunogenicity to the generation of antitumor cytotoxic cells in non-Hodgkin's lymphomas.
    Chaperot L; Jacob MC; Molens JP; Manches O; Bensa JC; Plumas J
    Leuk Lymphoma; 2000 Jul; 38(3-4):247-63. PubMed ID: 10830732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.